|
Progressive supranuclear palsy
|
0.300 |
Biomarker
|
disease |
CTD_human |
We also found SRSF2, as well as another tau splicing factor, TRA2B, to be increased in brains of PSP patients.
|
25402454 |
2014 |
|
Ophthalmoplegia, Progressive Supranuclear
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation.
|
25402454 |
2014 |
|
Supranuclear Palsy, Progressive, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation.
|
25402454 |
2014 |
|
Age at menarche
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Forced expiratory volume function
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry.
|
26634245 |
2015 |
|
response to bronchodilator
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry.
|
26634245 |
2015 |
|
Age at menarche
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche.
|
25231870 |
2014 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Specifically, the upregulation of SRSF4, SRSF6, or TRA2β disrupts acinar morphogenesis and promotes cell proliferation and invasion in MCF-10A cells.
|
31775037 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Moreover, siRNA-TRA2B transfection inhibited the invasion but accelerated apoptosis of EC cells.
|
31452736 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The results of the present study demonstrated that knockdown of Tra2β inhibits the proliferation and invasion of LSCC cells, at least partly via inhibiting PI3K/AKT signaling.
|
30597574 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Transformer-2 protein homolog beta (Tra2β) generally plays an important role in various human cancers, but its role and the underlying mechanisms in laryngeal squamous cell carcinoma (LSCC) remained unknown.
|
30597574 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overall, these findings suggest that the downregulation of miR-335 in A459 lung cancer cells promoted cell proliferation through upregulation of Tra2β, mediated via activation of the AKT/mTOR signaling pathway, and suggest that miR-335 may have potential as a novel therapeutic target for NSCLC.
|
29161765 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
TRA2B is associated with cancer cell survival and therapeutic sensitivity.
|
28416606 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
It demonstrated that Tra2β was expressed higher in NSCLC tumor tissues compared with adjacent non-tumor tissues.
|
24952301 |
2014 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrate that TRA2β is regulated by the MYC oncogene, plays a role in metastasis maintenance in vivo, and its levels correlate with breast cancer patient survival.
|
31775037 |
2019 |
|
Malignant neoplasm of endometrium
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among the dysregulated genes, the strongly upregulated TRA2B in the tissues and serum from patients with EC was selected for further analysis.
|
31452736 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Finally, we demonstrate that TRA2β is regulated by the MYC oncogene, plays a role in metastasis maintenance in vivo, and its levels correlate with breast cancer patient survival.
|
31775037 |
2019 |
|
Laryngeal Squamous Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Reverse-transcription quantitative polymerase chain reaction analysis and immunochemistry analysis indicated that the increased expression of Tra2β in LSCC was significantly associated with poor differentiation, lymph node metastasis, and advanced clinical stage.
|
30597574 |
2019 |
|
Endometrial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among the dysregulated genes, the strongly upregulated TRA2B in the tissues and serum from patients with EC was selected for further analysis.
|
31452736 |
2019 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrate that TRA2β is regulated by the MYC oncogene, plays a role in metastasis maintenance in vivo, and its levels correlate with breast cancer patient survival.
|
31775037 |
2019 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Here, we demonstrate that miR-335 expression is reduced in non-small cell lung cancer (NSCLC) tumors relative to non-cancerous adjacent tissues, while the expression of Tra2β is increased.
|
29161765 |
2018 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The splicing regulators Sam68 and Tra2β increase expression in prostate cancer.
|
28382513 |
2017 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The splicing regulators Sam68 and Tra2β increase expression in prostate cancer.
|
28382513 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
TRA2B is associated with cancer cell survival and therapeutic sensitivity.
|
28416606 |
2017 |
|
Squamous cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings improve our current knowledge of oncogenic drivers in lung SCC and provide a potential therapeutic strategy for lung SCC patients with TRA2B-DNAH5 fusion.
|
27670699 |
2016 |